ATE500503T1 - Cd86- und cd80-rezeptorkonkurrenztests - Google Patents

Cd86- und cd80-rezeptorkonkurrenztests

Info

Publication number
ATE500503T1
ATE500503T1 AT07762432T AT07762432T ATE500503T1 AT E500503 T1 ATE500503 T1 AT E500503T1 AT 07762432 T AT07762432 T AT 07762432T AT 07762432 T AT07762432 T AT 07762432T AT E500503 T1 ATE500503 T1 AT E500503T1
Authority
AT
Austria
Prior art keywords
receptor competition
competition tests
receptor
tests
antibodies
Prior art date
Application number
AT07762432T
Other languages
English (en)
Inventor
Robert M Townsend
Francisco Leon
Catherine A Fleener
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE500503T1 publication Critical patent/ATE500503T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Sampling And Sample Adjustment (AREA)
AT07762432T 2006-01-24 2007-01-23 Cd86- und cd80-rezeptorkonkurrenztests ATE500503T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US76162406P 2006-01-24 2006-01-24
US83201206P 2006-07-20 2006-07-20
US11/656,206 US7510844B2 (en) 2006-01-24 2007-01-22 CD86 and CD80 receptor competition assays
PCT/US2007/060893 WO2007087521A2 (en) 2006-01-24 2007-01-23 Cd86 and cd80 receptor competition assays

Publications (1)

Publication Number Publication Date
ATE500503T1 true ATE500503T1 (de) 2011-03-15

Family

ID=38198012

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07762432T ATE500503T1 (de) 2006-01-24 2007-01-23 Cd86- und cd80-rezeptorkonkurrenztests

Country Status (6)

Country Link
US (3) US7510844B2 (de)
EP (1) EP1984736B1 (de)
AT (1) ATE500503T1 (de)
CA (1) CA2638799C (de)
DE (1) DE602007012836D1 (de)
WO (1) WO2007087521A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2316026A1 (de) * 2008-07-25 2011-05-04 Merck Patent GmbH Verfahren zur bestimmung einer durch monoklonale antikörper hervorgerufenen rezeptorbindenden sättigung
KR101918456B1 (ko) * 2015-12-15 2018-11-16 앱클론(주) Cd80 및 cd86에 특이적으로 결합하는 항체
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018183929A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
RU2652885C1 (ru) * 2017-07-20 2018-05-03 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина " Минздрава России) Штамм гибридных культивируемых клеток животных mus musculus α - продуцент моноклональных антител, специфичных к раково-тестикулярному антигену человека GAGE
KR20250099256A (ko) 2018-01-18 2025-07-01 프레드 허친슨 캔서 센터 세포 활성화 상태를 조절함으로써 생체내 면역 세포의 염증 상태의 변경
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
EP3883635A1 (de) 2018-11-19 2021-09-29 Progenity, Inc. Verfahren und vorrichtungen zur behandlung einer krankheit mit biotherapeutika
WO2020140070A1 (en) * 2018-12-27 2020-07-02 Gigagen, Inc. Anti-b7-h4 binding proteins and methods of use thereof
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
WO1993002360A1 (en) 1991-07-16 1993-02-04 Transmed Biotech Incorporated Methods and compositions for simultaneous analysis of multiple analytes
US6084067A (en) 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
DE69739725D1 (de) * 1996-11-08 2010-02-11 Biogen Idec Inc Identifikation von bindungs- interaktionen zwischen gewissen antikorpern und den humanen costimulatorischen antigenen b7.1 (cd80) und b7.2 (cd28)
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
CN101255192A (zh) 2000-05-26 2008-09-03 布里斯托尔-迈尔斯斯奎布公司 可溶性ctla4突变体分子及其应用
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US7312086B2 (en) 2000-12-07 2007-12-25 Bristol-Myers Squibb Company Methods of diagnosing colon adenocarcinoma using the human g-protein coupled receptor hgprbmy23
US7304033B2 (en) 2001-05-23 2007-12-04 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules

Also Published As

Publication number Publication date
US20070172895A1 (en) 2007-07-26
WO2007087521A3 (en) 2007-11-01
US8378082B2 (en) 2013-02-19
US7510844B2 (en) 2009-03-31
EP1984736A2 (de) 2008-10-29
DE602007012836D1 (de) 2011-04-14
WO2007087521A2 (en) 2007-08-02
CA2638799A1 (en) 2007-08-02
CA2638799C (en) 2014-05-27
US20130197202A1 (en) 2013-08-01
EP1984736B1 (de) 2011-03-02
US8969531B2 (en) 2015-03-03
US20120077207A1 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
ATE500503T1 (de) Cd86- und cd80-rezeptorkonkurrenztests
ATE514755T1 (de) Fluoreszenzfarbstoffe zur verwendung bei der glukoseerfassung
WO2010065568A3 (en) METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
ATE517192T1 (de) Verfahren zur isolierung von zellen
WO2007100506A3 (en) Mass tags for quantitative analyses
IL195470A0 (en) Antibodies as t cell receptor mimics, methods of production and uses thereof
PH12016500658A1 (en) Human anti-alpha-synuclein autoantibodies
IL198185A (en) Testing Devices, Methods for Preparing and Testing Methods
IL179427A0 (en) Antibodies as t cell receptor mimics, methods of production and uses thereof
WO2011047087A3 (en) Protein detection via nanoreporters
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
WO2009129505A3 (en) Compositions, methods, and kits using synthetic probes for determining the presence of a target nucleic acid
WO2007084321A3 (en) Antibodies to ox-2/cd200 and uses thereof
MX344935B (es) Analisis para detectar anticuerpos especificos a anticuerpos anti-ige terapeuticos y su uso en anafilaxis.
MX345092B (es) Anticuerpos anti-tau humanos,.
GB201014805D0 (en) Microfluidics based assay device
WO2008073895A3 (en) Methods and devices for testing saliva
ATE504002T1 (de) Erkennung und vorhersage von frühgeburten
MX2010000680A (es) Materiales y metodos para selección de esperma sexual.
WO2009023331A3 (en) Antibodies and improved test sample handling methods for use in assays for myeloperoxidase
WO2007120766A3 (en) Erythropoietin receptor agonists
WO2012082742A3 (en) Detecting cancer with anti-ccl25 and anti-ccr9 antibodies
MX2010000979A (es) Metodos y composiciones para tratar enfermedad autoinmune.
WO2009132251A3 (en) Methods and compositions comprising anti-idiotypic antibodies to anti-mmp-14 antibodies
WO2008120006A3 (en) Diagnostic assay

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties